CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO
For many people, managing a disease means chronic therapy. Scribe Therapeutics has a different vision: genetic medicines that offer durable effects for the masses. With its lead program on a path to report its first human data next year, Scribe has joined …